Omeros

Developing drugs for inflammation, coagulopathies, and disorders of the central nervous system

placeSeattle, Washington, United States calendar_todayFounded 1994 groups276 employees language omeros.com

Registered entities

Innovation

144 patent families (98 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing, Emerging technologies; filing pace slowing. Cited 41,400 times.

YearFilings
201533
201652
201747
201846
201943
202039
202143
202241
202335
202436
202536
202613

Social engagement

Social engagement: 12.8K social following, 3 posts in the last 12 months — below the industry typical range.

Investor mix

21 investors on record; 2 have since exited.

Investor typeCountShare
Venture capital524%
Private equity733%
Bank & private debt314%
Other / undisclosed629%

Hiring activity

Hires occasionally

2 roles tracked across 2 of the last 12 months

3 Dec 2025 · Medical Science Liaison, West · San Francisco

Based on job postings tracked across public sources.

Recent activity

24 Dec 2025
Product launch
YARTEMLEA® (narsoplimab-wuug)
15 Oct 2025
Partnership
Omeros
Coming soon